Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04414618 · ClinicalTrials.gov registry record · Phase 2
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
A Phase 2 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT04414618 is a Phase 2 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 42 participants.
The verdict
NCT04414618, a Phase 2 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. 20 patients will receive opaganib in addition to standard of care twice each day for 14 days. 20 will receive matching placebo in addition to standard of care unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.
Interventions
- DRUG Placebo
- DRUG Opaganib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-07-02 |
| Est. Completion | 2020-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04414618
The ClinicalTrials.gov registry entry for NCT04414618 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04414618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04414618 about?
NCT04414618 is a clinical study titled "A Study of Opaganib in Coronavirus Disease 2019 Pneumonia". This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. 20 patients will receive opaganib in addition to...
What is the current status of trial NCT04414618?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2020-07-02. Estimated completion is 2020-12-23.
What interventions are being tested in trial NCT04414618?
The interventions under investigation include: Placebo (DRUG), Opaganib (DRUG).
Who is sponsoring clinical trial NCT04414618?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.